Toxys newsletter spring 2020

*|MC:SUBJECT|*
Toxys Newsletter March 2020
View this email in your browser
Toxys logo
ToxTracker Academy launched!
During the ToxTracker webinar which was held the 18th of May, ToxTracker Academy was launched. ToxTracker Academy is an expert center where you can learn about ToxTracker, find background information, webinars and instruction video’s, sign up for practical courses and trainings and find opportunities for collaboration. Check out the website!
Grant awarded: Framework and technology development for improving the quality of in vitro data

The consortium for the Create2Solve BID project, where Toxys participates in, was awarded a grant to further develop tools that control for the degradation, evaporation and binding of chemicals in in vitro toxicity testing systems. To reduce, replace and refine animal testing in regulatory toxicology, in vitro assays need to be accepted in OECD test guidelines (and sometimes also in an IATA), as only then, they can replace the animal tests now required for regulatory dossiers. For OECD acceptance, they need to enable in vitro-in vivo extrapolation (IVIVE) and be robust and reliable, among others, thus not provide different results over laboratories. The Good In Vitro Method Practices (GIVIMP) guidance document of the OECD describes the factors that need to be considered by assays developers, which should help speed up assay acceptance, and by end users. One of these factors is the control and monitoring of the exact test chemical exposure, which is only generally described. The work of this project gives in-depth practical guidance on which method for exposure control and monitoring to apply in which case. This should increase the application of exposure control and monitoring, leading to more robust and reliable in vitro assays and output suitable for IVIVE.

News in short

New Publications: 

A case study with triazole fungicides to explore practical application of next generation hazard assessment methods for human health.

The ongoing developments in chemical risk assessment have led to new concepts building on integration of sophisticated non-animal models for hazard characterization. In this paper a pragmatic approach for implementing such concepts is explored, using a case study of three triazole fungicides, i.e. flusilazole, propiconazole, and cyproconazole. The strategy applied starts with evaluating the overall level of concern by comparing exposure estimates to toxicological potential, followed by a combination of in silico tools and literature-derived high-throughput screening assays and computational elaborations to obtain insight into potential toxicological mechanisms and targets in the organism. ToxTracker was included in the evaluation of the fungicides. 

Job opportunities
Toxys is expanding and we are looking for a Director Marketing and Sales. Do you have a life science background, a flair for marketing and affinity with sales, then we are looking for you. Click here for the job description.

Events
Altertox/Toxys workshop: Novel in vitro methods and AOP approaches in genetic toxicology
On 7-8 July this workshop will be hosted in Leiden, the Netherlands. 
The program is being finalised and will be available soon. 
COVID-19 contingency planning and continuity of Toxys services

Toxys has been monitoring the global corona virus outbreak since the beginning of this year and is updating business continuity plans daily. We want to assure you that we remain dedicated to provide high quality services to our clients while also protecting the health of our employees.

Toxys closely follows the instructions from the Dutch national institute for public health. We recognise that the situation is evolving rapidly and we have taken proactive measures to mitigate  risk while maintaining business continuity.

  • The Toxys laboratories remain fully operational and continue to provide high quality services
  • The timelines for ToxTracker and other services have not changed
  • Toxys has sufficient certified lab personnel to ensure the continuity of all service activities
  • Our scientists and technical  experts remain available to support your projects

Despite the unprecedented circumstances, we remain committed to support our clients to develop better and safe products. Please contact us for more information.

Get in contact
We will attend and give presentations at several conferences. We are more than happy to meet alongside any of these meetings. If you are interested to learn more about our unique assays we could also schedule a TC to tell you more about our technologies and services.

Meetings we will attend
Given the Covid-19 situation many conferences have been cancelled. Instead of joining conferences we are open to scheduling TC's.

Please contact us if there are any questions: 

Paula van Rossum                          Pascal de Wit                               Ruairi Mac Siomoin
Director BD & Sales                        Business Developer                     Japan liaison (Eaolas Biosciences)
p.vanrossum@toxys.com                p.dewit@toxys.com                      macsiomoin@eolas-bio.co.jp   
+31 - 71 - 3322470                          +31 - 71 - 3322470                      +81-47-308-2204

Learn more about our unique services
LinkedIn
LinkedIn
Twitter
Twitter
Website
Website
Copyright © 2019, All rights reserved.

Our mailing address is:
info@toxys.com

Please visit our website for more information on our products and services and our privacy policy:
www.toxys.com

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to *|EMAIL|*
why did I get this?    unsubscribe from this list    update subscription preferences
*|LIST:ADDRESSLINE|*